Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
17 October 2024 - 10:15PM
Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company”
or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and medical countermeasures,
today announced that Gary Nabors, Ph.D., Chief Development Officer,
and key members of Appili’s scientific team, will participate at
IDWeek 2024™, and present an update on the Appili biodefense
program ATI-1701. The conference is being held from October 16-19
2024, at the Los Angeles Convention Center.
The poster presentation will provide an update
on ATI-1701, Appili’s potential first-in-class vaccine candidate
for the prevention of tularemia caused by F. tularensis and
will summarize the latest findings from preclinical studies. These
studies have demonstrated that a single dose of ATI-1701 provides
full protection in animal models against lethal tularemia one year
after vaccination.
Appili secured a US$14M funding commitment for
ATI-1701 from the United States Air Force Academy, who is working
in partnership with the Defense Threat Reduction Agency. These
funds along with other potential funding sources, are anticipated
to advance the ATI-1701 program to IND submission to the United
States Food and Drug Administration (“FDA”) in 2025.
“Appili and our government partners are greatly
encouraged by our manufacturing progress, and the results from the
365-day vaccination and challenge study,” said Dr. Gary Nabors,
Chief Development Officer. “These findings, along with government
funding commitments strengthen ATI-1701’s advanced development and
are expected to position the program for an IND submission in
2025.”
Presentation details for Appili are as
follows:
Poster Title: Toward the clinical development
of ATI-1701, a genetically defined live attenuated tularemia
vaccineDate: October 17th,
2024Time: 12:15 PM PT / 3:15 PM
ETLocation: Los Angeles Convention Center, Los
Angeles, CA, Hall J & K
Appili management is also in attendance at the
meeting and is available for in-person meetings throughout the
conference. To request a meeting with Appili, please contact
info@appilitherapeutics.com.
About ATI-1701ATI-1701 is a
novel, live-attenuated vaccine for F. tularensis, which causes
tularemia, a Category A pathogen which can be aerosolized and is
over 1,000 times more infectious than anthrax. Since it is a highly
infectious pathogen capable of causing severe illness, medical
countermeasures for F. tularensis are a top biodefense
priority for the United States and governments around the world.
There is currently no approved vaccine for the prevention of
tularemia in the United States or other major global markets.
About IDWeek 2024IDWeek 2024™
is an annual meeting of the Infectious Diseases Society of America
(IDSA), the Society for Healthcare Epidemiology of America (SHEA),
the HIV Medicine Association (HIVMA), the Pediatric Infectious
Diseases Society (PIDS) and the Society of Infectious Diseases
Pharmacists (SIDP). With the theme “Advancing Science, Improving
Care,” IDWeek features the latest science and bench-to-bedside
approaches in prevention, diagnosis, treatment and epidemiology of
infectious diseases, including HIV, across the lifespan. IDWeek
2024™ takes place Oct. 16-19 at the Los Angeles Convention Center
(1201 S Figueroa St) in Los Angeles, CA. For more information,
visit www.idweek.org.
About Appili TherapeuticsAppili
Therapeutics is an infectious disease biopharmaceutical company
that is purposefully built, portfolio-driven, and people-focused to
fulfill its mission of solving life-threatening infections. By
systematically identifying urgent infections with unmet needs,
Appili’s goal is to strategically develop a pipeline of novel
therapies to prevent deaths and improve lives. The Company is
currently advancing a diverse range of anti-infectives, including
an FDA approved ready-made suspension of metronidazole for the
treatment of antimicrobial infections, a vaccine candidate to
eliminate a serious biological weapon threat, and a topical
antiparasitic for the treatment of a disfiguring disease. Led by a
proven management team, Appili is at the epicenter of the global
fight against infection. For more information,
visit www.AppiliTherapeutics.com.
Forward Looking StatementsThis
news release contains “forward-looking statements”, including with
respect to the potential for ATI-1701 as a treatment for tularemia
and the proposed development plan for ATI-1701 (including the
timing of filing an IND). Wherever possible, words such as “may,”
“would,” “could,” “should,” “will,” “anticipate,” “believe,”
“plan,” “expect,” “intend,” “estimate,” “potential for” and similar
expressions have been used to identify these forward-looking
statements. These forward-looking statements reflect the current
expectations of the Company’s management for future growth, results
of operations, performance and business prospects and opportunities
and involve significant known and unknown risks, uncertainties and
assumptions, including, without limitation, those listed in the
annual information form of the Company dated June 25, 2024, and the
other filings made by the Company with the Canadian securities
regulatory authorities (which may be viewed
at www.sedarplus.ca). Should one or more of these risks or
uncertainties materialize or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
Media Contact:Jenna McNeil,
Corporate Affairs and Communications ManagerAppili TherapeuticsE:
JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:Don Cilla, Pharm.D.
M.B.A.Appili TherapeuticsE: Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Nov 2023 to Nov 2024